Curated News
By: NewsRamp Editorial Staff
May 28, 2025
NRx Pharmaceuticals Secures $7.8M Financing for HOPE Clinic Network Expansion
TLDR
- HOPE Therapeutics secures $7.8 million financing, advancing clinic acquisitions to support neuroplastic therapies for depression and PTSD.
- NRx Pharmaceuticals' subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital for clinic acquisitions.
- Expanding clinic network offers hope for mental health treatment through neuroplastic therapies, potentially improving outcomes for depression and PTSD patients.
- FDA waives $4.3 million drug application fee for NRx, possibly protecting NRX-100 through 2045, marking a significant development in mental health treatment.
Impact - Why it Matters
This news matters as NRx Pharmaceuticals advances its strategy to expand mental health clinic network and pursue FDA approval for its innovative therapies. The funding secured will support the acquisition of key clinics and the development of groundbreaking treatments for depression and PTSD.
Summary
NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, secured $7.8 million in debt financing for its subsidiary HOPE Therapeutics through a term sheet with Universal Capital. The total expected investment, when combined with a prior strategic investment, amounts to $10.3 million for acquisition funding of Dura Medical, Kadima, and NeuroSpa clinics. The expanding HOPE clinic network will offer neuroplastic therapies for depression and PTSD, including ketamine and TMS. Meanwhile, NRx continues to make regulatory progress for its NMDA-based therapies, with the FDA waiving a $4.3 million drug application fee for NRX-100 and potential patent protection through 2045.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NRx Pharmaceuticals Secures $7.8M Financing for HOPE Clinic Network Expansion
